Yousef Zakharia, MD, of University of Iowa Holden Comprehensive Cancer Center, continues his commentary on the phase Ib/II BTCRC-GU16-043 study investigating guadecitabine and durvalumab in advanced clear cell renal cell carcinoma (RCC). He notes any specific biomarkers that may predict response, as well as where he envisions the potential placement of the combination therapy in the treatment algorithm. ...